Microbot Medical (NASDAQ:MBOT - Get Free Report)'s stock had its "buy" rating reaffirmed by HC Wainwright in a report released on Thursday,Benzinga reports. They currently have a $9.00 price objective on the biotechnology company's stock. HC Wainwright's target price indicates a potential upside of 262.90% from the stock's previous close.
Microbot Medical Trading Up 8.8 %
Shares of NASDAQ:MBOT traded up $0.20 during midday trading on Thursday, reaching $2.48. 6,641,673 shares of the company were exchanged, compared to its average volume of 4,470,885. The stock has a market cap of $86.17 million, a PE ratio of -3.10 and a beta of 1.40. The business's fifty day moving average is $1.68 and its two-hundred day moving average is $1.39. Microbot Medical has a one year low of $0.82 and a one year high of $3.38.
Microbot Medical (NASDAQ:MBOT - Get Free Report) last released its quarterly earnings results on Wednesday, March 26th. The biotechnology company reported ($0.20) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.18) by ($0.02). As a group, sell-side analysts expect that Microbot Medical will post -0.71 EPS for the current year.
Institutional Inflows and Outflows
An institutional investor recently bought a new position in Microbot Medical stock. Renaissance Technologies LLC acquired a new position in Microbot Medical Inc. (NASDAQ:MBOT - Free Report) during the fourth quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor acquired 105,658 shares of the biotechnology company's stock, valued at approximately $118,000. Renaissance Technologies LLC owned 0.52% of Microbot Medical at the end of the most recent reporting period. 16.30% of the stock is owned by hedge funds and other institutional investors.
Microbot Medical Company Profile
(
Get Free Report)
Microbot Medical Inc, a pre-clinical medical device company, engages in the research, design, and development of robotic endoluminal surgery devices targeting the minimally invasive surgery space. The company offers LIBERTY, an endovascular robotic surgical system which allows physicians to conduct a catheter-based procedure from outside the catheterization laboratory, and avoid radiation exposure, physical strain, and the risk of cross contamination for use in cardiovascular, peripheral, and neurovascular spaces.
Read More
Before you consider Microbot Medical, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Microbot Medical wasn't on the list.
While Microbot Medical currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Enter your email address and we'll send you MarketBeat's list of ten stocks that are set to soar in Spring 2025, despite the threat of tariffs and other economic uncertainty. These ten stocks are incredibly resilient and are likely to thrive in any economic environment.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
